Who are venom immunotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PURETHAL Birch, 20.000 AUM/ml, ragweed pollen, Zopapogene imadenovec (Zopa), Staloral TM, tree 12 SQ-Bet, RAGWEED 12 AMB A 1-U.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/venom-immunotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

venom immunotherapy — Competitive Intelligence Brief

venom immunotherapy (venom immunotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunotherapy; desensitization therapy. Area: Immunology; Allergy.

marketed Immunotherapy; desensitization therapy Immunology; Allergy Small molecule Live · refreshed every 30 min

Target snapshot

venom immunotherapy (venom immunotherapy) — Meir Medical Center. Venom immunotherapy desensitizes patients to insect venom by gradually introducing increasing doses of venom extract to build immune tolerance.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
venom immunotherapy TARGET	venom immunotherapy	Meir Medical Center	marketed	Immunotherapy; desensitization therapy
PURETHAL Birch, 20.000 AUM/ml	PURETHAL Birch, 20.000 AUM/ml	HAL Allergy	marketed	Allergen immunotherapy extract	Birch pollen allergens (Bet v 1 and related proteins)
ragweed pollen	ragweed pollen	The University of Texas Medical Branch, Galveston	marketed	Allergen immunotherapy
Zopapogene imadenovec (Zopa)	Zopapogene imadenovec (Zopa)	Precigen, Inc	marketed	Oncolytic immunotherapy	Tumor cells (non-selective replication); immunostimulatory transgene product
Staloral TM	Staloral TM	National Taiwan University Hospital	marketed	Allergen immunotherapy
tree 12 SQ-Bet	tree 12 SQ-Bet	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen immunotherapy (sublingual tablet)	Tree pollen allergens (IgE cross-linking epitopes)
RAGWEED 12 AMB A 1-U	RAGWEED 12 AMB A 1-U	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen extract immunotherapy	Ragweed pollen allergens (Amb a 1 and related epitopes)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunotherapy; desensitization therapy class)

Meir Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). venom immunotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/venom-immunotherapy. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab